Opexa Therapeutics CEO Invited Panelist at 9th Annual Burrill Personalized Medicine Meeting

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K. Warma, Opexa’s President and Chief Executive Officer, has been invited as a panel member to participate in the 9th Annual Burrill Personalized Medicine Meeting. The event will take place September 30 - October 1, 2013 at the Bently Reserve & Conference Center in San Francisco.

Help employers find you! Check out all the jobs and post your resume.